Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT – Get Free Report) was the target of a large growth in short interest in May. As of May 15th, there was short interest totaling 148,551 shares, a growth of 96.2% from the April 30th total of 75,707 shares. Based on an average daily volume of 4,358,327 shares, the days-to-cover ratio is currently 0.0 days.
Lakewood-Amedex Biotherapeutics Stock Performance
Shares of NASDAQ:LABT opened at $0.65 on Tuesday. Lakewood-Amedex Biotherapeutics has a one year low of $0.61 and a one year high of $9.82.
Analysts Set New Price Targets
Separately, Wall Street Zen cut shares of Lakewood-Amedex Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday.
Lakewood-Amedex Biotherapeutics Company Profile
We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide.
See Also
- Five stocks we like better than Lakewood-Amedex Biotherapeutics
- Why These Three Big Buybacks Are Sending Very Different Signals to Investors
- Drone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked Name
- Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised Guidance
- Are the 3 Newest Members of the $1 Trillion Market Cap Club the Latest Sign of an AI Bubble?
Receive News & Ratings for Lakewood-Amedex Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakewood-Amedex Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
